Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Long-term Survival of Large Cell Neuroendocrine Lung Carcinoma with Bony Metastases: A Case of Immunoprotectivity?

Deborah Paul, Sarah Lander, Anna R. Cooper, Wakenda K. Tyler

Large cell neuroendocrine carcinoma (LCNEC) is a rare, highly malignant neoplasm with a dismal prognosis. The majority of patients will present with metastatic disease with a median overall survival of 6 months for this group. We present a case of metastatic LCNEC to the pelvis with a 10 year survival after tumor resection, radiation, and chemotherapy. We hypothesize that his survival and cancer stability are the result of an immune response brought on by a sub-acute turned chronic wound infection. After adjuvant therapies, he remained disease-free for 4 years until a recurrence in his lung and new metastases to his spine, which were treated with radiation. He remained disease-free for an additional 6 years, during which time, he discovered to have a chronic infection of his right femur with Staphylococcus Lugdunensis. To the best of our knowledge, this is the first long-term survivor of LCNEC with bony metastases.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.